Insulin spending topped $22bn in 2022 and its costs have tripled in the last decade, with major producers following last year’s Inflation Reduction Act and setting a $35 cap on out-of-pocket expenditure. Despite big three firms dominating the market with cheaper versions of branded products, new alternatives are emerging, such as Civica Rx, a nonprofit planning $30 per-vial insulin by 2024, and the state-run CalRx scheme that’s focusing first on insulin.
CISA Releases Security Advisory on 13 Industrial Control System Threats
The Cybersecurity and Infrastructure Security Agency (CISA) issued thirteen advisories to address vulnerabilities in industrial control systems (ICS), mainly in various Siemens systems and products
